Advertisement

Topics

BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

2015-03-24 04:37:45 | BioPortfolio

Published on BioPortfolio: 2015-03-24T04:37:45-0400

Clinical Trials [46 Associated Clinical Trials listed on BioPortfolio]

BAY38-9456 - Pivotal Trial for Diabetes Patient

The superiority of BAY 38-9456 10 mg and 20 mg regimens to placebo, and of 20 mg to 10 mg was confirmed in patients with diabetes mellitus suffering from erectile dysfunction. There was n...

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-Sparing Prostatectomy for Improving ED

A study to assess the efficacy of vardenafil, taken as a tablet both nightly or 'as needed' (immediately before intended sexual activity) compared to placebo, to evaluate its tolerability ...

Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction

Compare once daily vs on demand treatment in men with erectile dysfunction. Treatment of mild to moderate erectile dysfunction with 10 mg vardenafil p.o. over 24 weeks + 4 weeks wash-out:...

BAY38-9456 - Supportive Trial for Spinal Injury

BAY 38-9456 10 mg and 20 mg can be given as safe and efficacious medications to patients with spinal cord injury suffering from erectile dysfunction, and that erectile dysfunction can be i...

Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia

To demonstrate the efficacy, safety and tolerability of 10 mg oral vardenafil (BAY 38-9456) compared to placebo for a period of 12 weeks in men with erectile dysfunction (ED)

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of Vardenafil hydrochloride.

Vardenafil hydrochloride (VAR) is an erectile dysfunction treating drug. VAR has a short elimination half-life (4-5 h) and suffers low oral bioavailability (15%). This work aimed to explore the dual...

Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability.

Vardenafil hydrochloride is commonly used for the curing of erectile dysfunction. VAR suffers certain limitations: (i) short elimination half-life (4-5 h), (ii) low aqueous solubility (0.11 mg/mL), ...

Determination of the illegal adulteration of natural healthcare products with chemical drugs using surface-enhanced Raman scattering.

The illegal adulteration of natural healthcare products with chemical drugs can result in serious health risks for consumers. Thus there is an urgent need for a fast and precise detection method. In t...

Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?

Appropriate algorithms for the prediction of cardiovascular risk are strongly suggested in clinical practice, although still controversial. In type 2 diabetes mellitus (T2DM), the beneficial effect of...

Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.

Cyclic nucleotides cAMP and cGMP cooperate to ensure memory acquisition and consolidation. Increasing their levels by phosphodiesterase inhibitors (PDE-Is) enhanced cognitive functions and rescued mem...

Medical and Biotech [MESH] Definitions

A piperazine derivative, PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION.

More From BioPortfolio on "BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration."

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial